Inactive Instrument

News Celsion Corporation Nasdaq

Stocks

US15117N3052

Biotechnology & Medical Research

End-of-day quote Nasdaq
- ^USD	-

09-24	IMUNON, Inc. Presents Update On IMNN-001 Development Program For Women With Newly Diagnosed Advanced Ovarian Cancer	CI
09-23	Imunon, Inc. - Shareholder/Analyst Call

All News

Mentions Relevance

10-08	IMUNON to Participate in Upcoming Investor Conferences	AQ
09-29	IMUNON Converts $1.2 Million of Debt-to-Equity	AQ
09-24	IMUNON, Inc. Presents Update On IMNN-001 Development Program For Women With Newly Diagnosed Advanced Ovarian Cancer	CI
09-24	IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan	AQ
09-23	Imunon, Inc. - Shareholder/Analyst Call
09-22	IMUNON, Inc. Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development Of IMNN-001 Following Favorable Safety Review	CI
09-22	IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review	AQ
09-10	Imunon, Inc. Enters Cooperative Research and Development Agreement with National Cancer Institute	CI
09-10	IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001	AQ
09-09	IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress	AQ
08-26	IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001	AQ
08-26	IMUNON Hosts 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial And Clinical Potential Of IMNN-001	CI
08-11	Imunon, Inc., Q2 2026 Earnings Call, Aug 11, 2026
08-11	Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-11	IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
08-04	IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026	AQ
07-30	IMUNON Reports Strong Enrollment Momentum In Phase 3 OVATION 3 Trial Of IMNN-001 In Advanced Ovarian Cancer	CI
07-30	Imunon Reports Enrollment Above Expectations in Phase 3 Trial of IMNN-001 to Treat Ovarian Cancer	MT
07-30	IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer	AQ
07-23	IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development	AQ
07-21	Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response	MT
07-21	IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer	AQ
06-30	Imunon, Inc. Appoints Josh Blacher as Principal Financial Officer and Principal Accounting Officer, Effective July 1, 2026	CI
06-30	Imunon, Inc. Announces Chief Financial Officer Changes, Effective July 1, 2026	CI
06-23	IMUNON Inc. Continues Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Chemotherapy	CI